https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-11-28 / Cancer Immunol. Immunother. 2007 Jul;56(7):1025-36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-11-28 / Cancer Immunol. Immunother. 2007 Jul;56(7):1025-362006-11-28 00:00:002019-02-15 08:38:12Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-11-28 / Zhonghua Yi Xue Za Zhi 2006 Nov;86(44):3122-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-11-28 / Zhonghua Yi Xue Za Zhi 2006 Nov;86(44):3122-72006-11-28 00:00:002006-11-28 00:00:00[Immune response of heparinase gene modified dendritic cell-based vaccine on gastric cancer cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-11-15 / Cancer Immunol. Immunother. 2007 Jun;56(6):897-903
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-11-15 / Cancer Immunol. Immunother. 2007 Jun;56(6):897-9032006-11-15 00:00:002019-02-15 09:16:59Antigen-independent immune responses after dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-11-15 / Int. J. Cancer 2006 Nov;119(10):2428-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-11-15 / Int. J. Cancer 2006 Nov;119(10):2428-342006-11-15 00:00:002019-02-15 09:24:12Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-11-01 / Gan To Kagaku Ryoho 2006 Nov;33(12):1739-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-11-01 / Gan To Kagaku Ryoho 2006 Nov;33(12):1739-412006-11-01 00:00:002019-02-15 08:44:38[Successful immunotherapy combined with hyperthermia therapy for cancer patients]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-11-01 / Neurosurgery 2006 Nov;59(5):988-99; discussioin 999-1000
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-11-01 / Neurosurgery 2006 Nov;59(5):988-99; discussioin 999-10002006-11-01 00:00:002021-11-15 15:39:05Dendritic cell vaccination in patients with malignant gliomas: current status and future directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-11-01 / Cancer Res. 2006 Nov;66(21):10247-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-11-01 / Cancer Res. 2006 Nov;66(21):10247-522006-11-01 00:00:002019-02-15 08:59:57Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-11-01 / Curr Opin Oncol 2006 Nov;18(6):631-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-11-01 / Curr Opin Oncol 2006 Nov;18(6):631-62006-11-01 00:00:002019-02-15 08:59:57Recent advances in immunotherapy for human glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-11-01 / In Vivo 2006 Nov-Dec;20(6A):721-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-11-01 / In Vivo 2006 Nov-Dec;20(6A):721-42006-11-01 00:00:002019-02-15 09:00:11A phase II clinical study on relapsed malignant gliomas treated with electro-hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-11-01 / Int J Hyperthermia 2006 Nov;22(7):613-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-11-01 / Int J Hyperthermia 2006 Nov;22(7):613-212006-11-01 00:00:002006-11-01 00:00:00Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma
